2. Search Result
Search Result
Results for "

Small+Molecules+Inhibitors

" in MedChemExpress (MCE) Product Catalog:

129

Inhibitors & Agonists

5

Screening Libraries

1

Fluorescent Dyes

4

Peptides

1

Inhibitory Antibodies

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150031
    MFI8
    5+ Cited Publications

    		 Mitochondrial Metabolism Others
    MFI8 is a small molecule inhibitor of mitochondrial .
    MFI8
  • HY-101091
    Importazole
    15+ Cited Publications

    		 Apoptosis Cancer
    Importazole is a small molecule inhibitor of the nuclear transport receptor importin-β.
    Importazole
  • HY-19707
    4μ8C
    Maximum Cited Publications
    69 Publications Verification

    IRE1 Inhibitor III

    		 IRE1 Metabolic Disease
    4μ8C (IRE1 Inhibitor III) is a small-molecule inhibitor of IRE1α.
    4μ8C
  • HY-129039
    Butyrolactone 3
    10+ Cited Publications

    MB-3

    		 Histone Acetyltransferase Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Butyrolactone 3 (MB-3) is a specifical small-molecule inhibitor of the histone acetyltransferase Gcn5 (IC50=100 μM), which has a high affinity to the Gcn5 enzyme comparable to that of its natural substrate, histone H3. Butyrolactone 3 shows weak inhibitory on CBP (IC50=0.5 mM). Butyrolactone 3 can be used in studies of cancer, metabolic, autoimmune and neurological diseases .
    Butyrolactone 3
  • HY-152857
    Muvalaplin

    LY3473329

    		 LDLR Cardiovascular Disease
    Muvalaplin (LY3473329) is an orally active, selective small molecule inhibitor of lipoprotein (a) (Lp (a)) that disrupts the initial non-covalent interaction between apo(a) and apoB100, preventing the disulphide bond and Lp(a) formation. Muvalaplin reduces the levels of Lp (a) in transgenic mice and in cynomolgus monkeys .
    Muvalaplin
  • HY-103045
    CMPD101
    4 Publications Verification

    		 ROCK PKC G Protein-coupled Receptor Kinase (GRK) Cardiovascular Disease
    CMPD101 is a potent, highly selective and membrane-permeable small-molecule inhibitor of GRK2/3 with IC50 of 18 nM and 5.4 nM, respectively. CMPD101 exhibits less selectively against GRK1, GRK5, ROCK-2 and PKCα with IC50s of 3.1 μM , 2.3 μM, 1.4 μM and 8.1 μM, respectively. CMPD101 can be used for the study of heart failure .
    CMPD101
  • HY-16925
    MI-503
    5+ Cited Publications

    		 Epigenetic Reader Domain Cancer
    MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.
    MI-503
  • HY-50295
    CI-1040
    20+ Cited Publications

    PD 184352

    		 MEK Apoptosis Cancer
    CI-1040 (PD 184352) is an orally active, highly specific, small-molecule inhibitor of MEK with an IC50 of 17 nM for MEK1.
    CI-1040
  • HY-173629
    RMC-5127

    		Ras Apoptosis Cancer
    RMC-5127 is a small molecule inhibitor that binds to GTP-targeted KRAS G12V, with oral bioavailability and blood-brain barrier permeability. RMC-5127 inhibits the activities of the RAS and MAPK pathways, suppresses the proliferation of KRAS G12V-mutant cancer cells and induces their apoptosis. RMC-5127 can be used for the research of KRAS G12V-mutant non-small cell lung cancer, pancreatic ductal adenocarcinoma, colorectal cancer and intracranial KRAS G12V tumors .
    RMC-5127
  • HY-125017
    Bozitinib
    1 Publications Verification

    PLB-1001; CBT-101; Vebreltinib

    		 c-Met/HGFR Cancer
    Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily .
    Bozitinib
  • HY-12302
    Kenpaullone
    10+ Cited Publications

    9-Bromopaullone; NSC-664704

    		 CDK GSK-3 Cancer
    Kenpaullone is a potent inhibitor of CDK1/cyclin B and GSK-3β, with IC50s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC50s of 0.68 μM, 7.5 μM, 0.85 μM, respectively. Kenpaullone, a small molecule inhibitor of KLF4, reduces self-renewal of breast cancer stem cells and cell motility in vitro.
    Kenpaullone
  • HY-100493
    BP-1-102
    10+ Cited Publications

    		 STAT Cancer
    BP-1-102 is an orally available, small-molecule inhibitor of transcription factor Stat3, with an IC50 of 6.8 μM.
    BP-1-102
  • HY-10527
    Telatinib
    1 Publications Verification

    Bay 57-9352

    		 c-Kit PDGFR VEGFR Cancer
    Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit with IC50s of 6, 4, 15 and 1 nM, respectively.
    Telatinib
  • HY-150190
    F5446
    1 Publications Verification

    		 Histone Methyltransferase Apoptosis Cancer
    F5446 (Compound 1) is a selective small molecule inhibitor of SUV39H1 methyltransferase. F5446 decreases H3K9me3 deposition at the FAS promoter, increases Fas expression and increases colorectal carcinoma cell sensitivity to FasL-induced apoptosis in vitro. F5446 suppresses human colon tumor xenograft growth in vivo .
    F5446
  • HY-122611A
    CSRM617 hydrochloride
    1 Publications Verification

    		 Androgen Receptor Apoptosis Cancer
    CSRM617 hydrochloride is a selective small-molecule inhibitor of the transcription factor ONECUT2 (OC2, a master regulator of androgen receptor) with a Kd of 7.43 uM in SPR assays, binding to OC2-HOX domain directly. CSRM617 hydrochloride induces apoptosis by appearance of cleaved Caspase-3 and PARP. CSRM617 hydrochloride is well tolerated in the prostate cancer mouse model
    CSRM617 hydrochloride
  • HY-19546
    BAY-598
    5+ Cited Publications

    		 Histone Methyltransferase Cancer
    BAY-598, a chemical probe, is selective small molecule inhibitor of SMYD2 with an IC50 of 27 nM .
    BAY-598
  • HY-15755
    RKI-1447
    4 Publications Verification

    		 ROCK Cancer
    RKI-1447 is a potent small molecule inhibitor of ROCK1 and ROCK2 with IC50 values of 14.5 nM and 6.2 nM, respectively.
    RKI-1447
  • HY-19536
    LLL12
    1 Publications Verification

    		 STAT Cancer
    LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth .
    LLL12
  • HY-19809
    MI-463
    2 Publications Verification

    		 Epigenetic Reader Domain Cancer
    MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.
    MI-463
  • HY-159644
    Casdatifan

    AB521

    		 HIF/HIF Prolyl-Hydroxylase VEGFR Cancer
    Casdatifan (AB521) is an orally active and selective allosteric small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α). Casdatifan inhibits pro-tumor gene transcription by blocking the heterodimerization of HIF-2α with ARNT, and significantly suppresses tumor growth in clear cell renal cell carcinoma (ccRCC) models either as a monotherapy or in combination with agents such as Zimberelimab (HY-P99109). Casdatifan is applicable for the research of ccRCC .
    Casdatifan
  • HY-49116
    CP26

    		E1/E2/E3 Enzyme Infection Inflammation/Immunology
    CP26 is a small molecule inhibitor of protein dislocation from the ER lumen to the cytosol. CP26 targets the Hrd1 complex, inhibits ERAD, and induces ER stress .
    CP26
  • HY-10704
    PTP1B-IN-1
    5 Publications Verification

    PTP1B inhibitor

    		 Phosphatase NF-κB Neurological Disease Inflammation/Immunology
    PTP1B-IN-1 (Compound 7a) is a small molecule inhibitor of PTP1B with an IC50 value of 1.6 mM. It is often used as the mother core for derivatives of analogues .
    PTP1B-IN-1
  • HY-144987
    RBN013209
    1 Publications Verification

    		 CD38 LAG-3 Tim3 PD-1/PD-L1 Inflammation/Immunology Cancer
    RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD + to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors .
    RBN013209
  • HY-17641
    Olumacostat glasaretil

    DRM01

    		 Acetyl-CoA Carboxylase Others
    Olumacostat glasaretil (DRM01) is a small molecule inhibitor of acetyl coenzyme A carboxylase (ACC).
    Olumacostat glasaretil
  • HY-145334
    CD73-IN-5

    		CD73 Cancer
    CD73-IN-5 is a potent and selective non-nucleotide small molecule inhibitor of CD73 (IC50 = 19 nM).
    CD73-IN-5
  • HY-138617
    AI-10-47
    1 Publications Verification

    		 RUNX Cancer
    AI-10-47 is a small molecule inhibitor of CBFβ-RUNX binding, with an IC50 of 3.2 μM .
    AI-10-47
  • HY-16664
    SJ-172550
    2 Publications Verification

    		 MDM-2/p53 E1/E2/E3 Enzyme Cancer
    SJ-172550 is a small molecule inhibitor of MDMX; competes for the wild type p53 peptide binding to MDMX with an EC50 of 5 μM.
    SJ-172550
  • HY-10398
    CTS-1027
    4 Publications Verification

    Ro 1130830; RS 130830

    		 MMP Cancer
    CTS-1027 is a potent small molecule inhibitor of MMPs, with IC50s of 0.3 nM, 0.5 nM for MMP2, MMP13, respectively, and has > 1,000 fold selectivity over MMP1.
    CTS-1027
  • HY-19748
    LED209

    		Bacterial Infection
    LED209 is a potent and orally active small molecule inhibitor of the bacterial receptor QseC and a potent prodrug with high selectivity for QseC. LED209 inhibits the binding of signaling molecules to QseC. LED209 has antibacterial activity .
    LED209
  • HY-125471
    VK-1727
    1 Publications Verification

    		 EBV Infection Inflammation/Immunology Cancer
    VK-1727 is a selective small molecule inhibitor of EBNA1. VK-1727 can reduce EBNA1 DNA binding activity. VK-1727 selectively blocks the proliferation and metabolic activity of EBV+ cells, instead of EBV- cells. VK-1727 is used in multiple sclerosis research .
    VK-1727
  • HY-162859
    AB25583
    1 Publications Verification

    		 DNA/RNA Synthesis Cancer
    AB25583 is a Polθ helicase (Polθ-hel) small molecule inhibitor, with an IC50 value of 6 nM. AB25583 selectively kills BRCA1/2 deficient cells and works in synergy with Olaparib (HY-10162) in cancer cells carrying pathogenic BRCA1/2 mutations. AB25583 can be used for tumor research .
    AB25583
  • HY-161138
    WK369

    		BCL6 Apoptosis Cancer
    WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A .
    WK369
  • HY-135813
    LtaS-IN-1
    1 Publications Verification

    		 Bacterial Infection
    LtaS-IN-1 (compound 1771) is a potent small-molecule inhibitor of Lipoteichoic acid (LTA) synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology. LtaS-IN-1 alone inhibits Enterococcus.spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 combination with antibiotics abolishs multidrug-resistant E. faecium growth almost completely .
    LtaS-IN-1
  • HY-141852
    STAMBP-IN-1

    		Deubiquitinase Inflammation/Immunology
    STAMBP-IN-1 is a small-molecule inhibitor of STAMBP deubiquitinase, and interrupts STAMBP-Ub-NALP7 interaction. STAMBP-IN-1 decreases protein level of its inflammasome substrate NALP7 and suppresses IL-1b release after Toll-like receptor (TLR) agonism. STAMBP-IN-1 inhibits the activity of STAMBP to cleave recombinant di-Ub with an IC50 value of 0.33 mM .
    STAMBP-IN-1
  • HY-132850
    Dazcapistat

    BLD-2660

    		 Proteasome Interleukin Related Infection Inflammation/Immunology
    Dazcapistat (BLD-2660) is an orally active small-molecule inhibitor of calpain 1, 2, and 9 (calpain 1, 2, 9). Dazcapistat reduces the expression/production level of IL-6 in injured lung tissue and alleviates fibrosis . Dazcapistat exerts anti-fibrotic effects in various animal models of fibrosis in the skin, liver and lung . Dazcapistat can be used in research related to coronavirus disease 2019 (COVID-19) and idiopathic pulmonary fibrosis .
    Dazcapistat
  • HY-13301
    MPC-3100

    		HSP Cancer
    MPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of Hsp90 with potential antineoplastic activity .
    MPC-3100
  • HY-W771599
    ASC-69

    APY69

    		 PD-1/PD-L1 Cancer
    ASC-69 (APY69)is a potent and promising?PD-1/PD-L1 small-molecule inhibitor .
    ASC-69
  • HY-136797
    BP13944

    		Dengue Virus Infection
    BP13944 is a potential small molecule inhibitor discovered by high-throughput screening. It can effectively inhibit the expression of dengue virus (DENV) replicons with an EC50 value of 1.03±0.09 μM. BP13944 can inhibit the replication or viral RNA synthesis of all four serotypes of DENV, but is ineffective against Japanese encephalitis virus. BP13944 may target the DENV NS3 protease, and the E66G amino acid substitution in the NS3 protease region will cause the virus to become resistant to BP13944. BP13944 has no obvious cytotoxicity. As there is currently no effective dengue vaccine and treatment, BP13944, as an effective small molecule inhibitor, may become a potential agent for the treatment of dengue in the future.
    BP13944
  • HY-117233
    UU-T02
    1 Publications Verification

    		 β-catenin Wnt Metabolic Disease Cancer
    UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) with a Ki of 1.36 μM . UU-T02 inhibits canonical Wnt signaling and the growth of colorectal cancer cells .
    UU-T02
  • HY-163565
    BIIB129

    		Btk Neurological Disease
    BIIB129 is a covalent, selective, small molecule inhibitor of Bruton's tyrosine kinase (BTK) capable of penetrating the blood-brain barrier. BIIB129 inhibits the activity of BTK by covalently binding to Cys481 in BTK, thereby affecting the function of B cells and myeloid cells. BIIB129 can be used in multiple sclerosis (MS) research .
    BIIB129
  • HY-P1805
    Calmodulin Binding Peptide 1

    		Calmodulin Neurological Disease
    Calmodulin Binding Peptide 1 is a high-affinity (pM) CaM-binding peptide derived from smooth muscle myosin light chain kinase (MLCK peptide). The interface of the complex formed by Calmodulin Binding Peptide 1 and Ca 2+-CaM can be specifically bound by small-molecule inhibitors, serving as a key target for selective regulation of smooth muscle contraction and development of anti-CaM drugs .
    Calmodulin Binding Peptide 1
  • HY-171180
    AF615

    		DNA/RNA Synthesis Cancer
    AF615 is a small molecule inhibitor targeting the CDT1/Geminin protein complex (IC50 = 0.313 μM). AF615 selectively induces DNA damage, inhibits DNA synthesis, causes cell cycle arrest, and decreases the survival rate in cancer cell lines. AF615 displayed a Ki = 0.37 μM in case of Geminin-tCDT1 interaction and a Ki = 0.75 μM in case of Geminin-miniCDT1 interaction .
    AF615
  • HY-178124
    Huib32

    		Deubiquitinase Neurological Disease Cancer
    Huib32 is a potent small-molecule inhibitor of USP32 (IC50 = 21.2 nM), exhibiting high selectivity over other closely related deubiquitinating enzymes (DUBs), such as USP8/10/16, UCHL1 and OTUB2. Huib32 reversibly inhibits USP32 by covalently binding to the active site Cys743, which enhances substrate ubiquitination, alters endosomal morphology, and mimics USP32 depletion. Huib32 can be used for breast, ovarian, and lung cancer and Alzheimer's and Parkinson’s diseases research .
    Huib32
  • HY-148138
    Deaminase inhibitor-1

    		HIV Infection
    Deaminase inhibitor-1 is a small molecule inhibitor of APOBEC3G DNA Deaminase, with an IC50 value of 18.9 μM .
    Deaminase inhibitor-1
  • HY-143539
    YQ456

    		Ferlin Family Cancer
    YQ456 is a novel small molecule inhibitor of myoferlin that showed high binding affinity to myoferlin with a KD of 37 nM and excellent anti-invasion capability with an IC50 of 110 nM.
    YQ456
  • HY-163542
    Pneumolysin-IN-1

    		Bacterial Inflammation/Immunology
    Pneumolysin-IN-1 (compound PB-3) is a targeted small molecule inhibitor of Pneumolysin (PLY) (IC50=3.1 µM). Pneumolysin-IN-1 is a pore blocking agent and an anti-virulence factor. Pneumolysin-IN-1 can be used to study the infection caused by Streptococcus pneumoniae .
    Pneumolysin-IN-1
  • HY-155888
    IV-255

    		Epigenetic Reader Domain Cancer
    IV-255 is a selective small molecule inhibitor of the BRG1 bromodomain. IV-255 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345). IV-255 inhibits the invasiveness of GBM cells. IV-255 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide .
    IV-255
  • HY-169090
    TS-002902

    		DNA/RNA Synthesis Cancer
    TS-002902 is a selective small-molecule inhibitor of TUT4 and TUT7 enzymes, with IC50 values of 0.36 nM and 9.6 nM, respectively. TS-002902 induces an antiproliferative effect in FOCAD-deficient cancer cells. TS-002902 is applicable for research on FOCAD-deficient solid tumors (including glioblastoma, non-small cell lung cancer, and pancreatic cancer) .
    TS-002902
  • HY-174066
    SI-W052

    		mTOR Autophagy Interleukin Related Neurological Disease Inflammation/Immunology
    SI-W052 is an orally active, brain-penetrant and selective small-molecule inhibitor targeting mTOR and TEX264. SI-W052 activates autophagy by inhibiting mTOR phosphorylation and enhances TEX264 expression to promote ER turnover, suppressing LPS-induced release of inflammatory factors (TNF-α, IL-6). SI-W052 is promising for research of Alzheimer’s disease (AD)-associated neuroinflammation .
    SI-W052
  • HY-163562
    JYQ-164

    		PINK1/Parkin Neurological Disease Cancer
    JYQ-164 is a small molecule inhibitor of Parkinson's disease protein 7 (PARK7/DJ-1) in humans. JYQ-164 works by covalently and selectively targeting Cys106, a key residue of PARK7 (IC50=21 nM). The high inhibitory effect of JYQ-164 on PARK7 is 5 times more potent than the previously reported inhibitor JYQ-88. JYQ-164 can be used in Parkinson's disease and cancer research .
    JYQ-164

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: